guest ::
| Home > Publications database > ATRX loss in adult gliomas lacking H3 alterations or IDH mutations, an exceptional situation for exceptional diagnoses: the experience of Sainte-Anne hospital. |
| Home > Publications database > ATRX loss in adult gliomas lacking H3 alterations or IDH mutations, an exceptional situation for exceptional diagnoses: the experience of Sainte-Anne hospital. |
| Journal Article | DKFZ-2025-01226 |
; ; ; ; ; ; ; ; ; ; ; ; ; ;
2025
Biomed Central
London
This record in other databases: 
Please use a persistent id in citations: doi:10.1186/s40478-025-02044-6
Abstract: ATRX immunostaining constitutes a routinely used biomarker for the practice of neuropathology. The loss of ATRX expression correlating with ATRX gene alterations is implicated in a wide variety of pediatric and adult gliomas, and has been indexed as a desirable or essential diagnostic criterion for four tumor types featured in the latest world health organization classification of central nervous system Tumors. In adult-type diffuse glioma, the loss of ATRX expression is a hallmark of astrocytoma, IDH-mutant. Recently, novel tumor types and alterations have been referenced in the literature. These include the high-grade astrocytoma with piloid features (HGAP), for which no consistent clinicopathological features have been defined, and the presence of other alterations in the Krebs cycle genes (variants of the Fumarate hydratase -FH- gene) found in gliomas resembling astrocytomas, IDH-mutant. Because of this rapidly evolving classification and histomolecular landscape, we retrospectively analyzed adult gliomas diagnosed over a four consecutive year period to identify supratentorial gliomas, lacking H3 alterations or IDH mutations and harboring a loss of ATRX expression, in order to update their diagnoses in terms of histopathology, genetics and epigenetics. Four specimens (from 620 adult gliomas, 0.7%) were reclassified at the end of the molecular workup, as: 1/ one HGAP, 2/ one malignant transformation with a primitive neuronal component of an astrocytoma, IDH-mutant which lost the IDH2 mutation at recurrence, 3/ a glioma, FH-mutant for which the histopathological and epigenetic features were similar to an astrocytoma, IDH-mutant, and 4/ a glioblastoma, IDH-wildtype. To conclude, these exceptional cases extend the spectrum of ATRX loss in gliomas, beyond the astrocytoma, IDH-mutant and the diffuse hemispheric glioma, H3 G34-mutant.
Keyword(s): Humans (MeSH) ; X-linked Nuclear Protein: genetics (MeSH) ; X-linked Nuclear Protein: metabolism (MeSH) ; Glioma: genetics (MeSH) ; Glioma: diagnosis (MeSH) ; Glioma: pathology (MeSH) ; Glioma: metabolism (MeSH) ; Isocitrate Dehydrogenase: genetics (MeSH) ; Female (MeSH) ; Male (MeSH) ; Adult (MeSH) ; Middle Aged (MeSH) ; Brain Neoplasms: genetics (MeSH) ; Brain Neoplasms: diagnosis (MeSH) ; Brain Neoplasms: pathology (MeSH) ; Brain Neoplasms: metabolism (MeSH) ; Mutation: genetics (MeSH) ; Aged (MeSH) ; Retrospective Studies (MeSH) ; Histones: genetics (MeSH) ; Young Adult (MeSH) ; ATRX ; Diffuse glioma ; FH ; HGAP ; X-linked Nuclear Protein ; ATRX protein, human ; Isocitrate Dehydrogenase ; Histones
; 
; Article Processing Charges ; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; DOAJ Seal ; Ebsco Academic Search ; Essential Science Indicators ; Fees ; IF >= 5 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
|
The record appears in these collections: |
